Table 1 Socio-demographic characteristics and medical data of patients
Total (n = 140) | CAM users (n = 97) | CAM non-users (n = 43) | p-valuec | |
|---|---|---|---|---|
Age, years, mean (SD) | 12.3 (5.4) | 12.0 (4.8) | 12.8 (6.5) | 0.51d |
Age categories, years | 0.05 | |||
< 2 | 1 (0.7) | 0 (0) | 1 (2.3) | |
2–4 | 8 (5.7) | 3 (3.1) | 5 (11.6) | |
5–7 | 21 (15.0) | 15 (15.5) | 6 (14.0) | |
8–12 | 55 (39.3) | 43 (44.3) | 12 (27.9) | |
13–18 | 36 (25.7) | 26 (26.8) | 10 (23.3) | |
> 18 | 19 (13.6) | 10 (10.3) | 9 (20.9) | |
Age at diagnosis,a years, mean (SD) | 7.1 (5.0) | 7.0 (4.6) | 7.5 (5.7) | 0.59d |
Child’s genderb | 0.46 | |||
Female | 69 (49.3) | 50 (51.6) | 19 (44.2) | |
Male | 71 (50.7) | 47 (48.5) | 24 (55.8) | |
Time intervals since diagnosis at time of study | 0.03 | |||
During OT | 15 (10.7) | 10 (10.3) | 5 (11.6) | |
1st year after the end of OT | 19 (13.6) | 9 (9.3) | 10 (23.3) | |
Between 1 and 5 years after the end of OT | 52 (37.1) | 43 (44.3) | 9 (20.9) | |
≥ 5 years after the end of OT | 50 (35.7) | 33 (34.0) | 17 (39.5) | |
Other (recurrence or 2nd cancer) | 4 (2.9) | 2 (2.1) | 2 (4.7) | |
Type of cancer | 0.51 | |||
Leukemia | 42 (30.0) | 30 (30.9) | 12 (27.9) | |
Malignant solid tumors | 42 (30.0) | 29 (30.0) | 13 (30.2) | |
Leukemia/malignant solid tumors | 3 (2.1) | 3 (3.1) | 0 (0.0) | |
Central nervous system (including retinoblastoma) | 34 (24.3) | 25 (25.8) | 9 (20.9) | |
Lymphoma | 13 (9.3) | 7 (7.2) | 6 (14.0) | |
Other | 6 (4.3) | 3 (3.1) | 3 (7.0) | |
Treatment received (4 different binary variables) | ||||
Chemotherapy | 106 (76.3) | 73 (76.0) | 33 (76.7) | 0.64 |
Surgery | 82 (58.6) | 56 (57.7) | 26 (60.5) | 0.85 |
Radiotherapy | 33 (23.6) | 22 (22.7) | 11 (25.6) | 0.83 |
Stem cell transplantation | 16 (11.4) | 14 (14.4) | 2 (4.7) | 0.15 |
CAM supplemental healthcare insurance | 0.004 | |||
Yes | 102 (72.9) | 78 (80.4) | 24 (55.8) | |
No | 28 (20.0) | 16 (16.5) | 12 (27.9) | |
Don’t know | 10 (7.1) | 3 (3.1) | 7 (16.3) | |